SE9401091D0 - Alphavirus cDNA vectors - Google Patents

Alphavirus cDNA vectors

Info

Publication number
SE9401091D0
SE9401091D0 SE9401091A SE9401091A SE9401091D0 SE 9401091 D0 SE9401091 D0 SE 9401091D0 SE 9401091 A SE9401091 A SE 9401091A SE 9401091 A SE9401091 A SE 9401091A SE 9401091 D0 SE9401091 D0 SE 9401091D0
Authority
SE
Sweden
Prior art keywords
present
cdna
polynucleotide molecules
animal
desired products
Prior art date
Application number
SE9401091A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Liljestroem
Henrik Garoff
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9401091(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Priority to SE9401091A priority Critical patent/SE9401091D0/xx
Publication of SE9401091D0 publication Critical patent/SE9401091D0/xx
Priority to AU21557/95A priority patent/AU699384B2/en
Priority to EP95914666A priority patent/EP0753053B1/en
Priority to DK95914666T priority patent/DK0753053T3/da
Priority to CA002184261A priority patent/CA2184261A1/en
Priority to ES95914666T priority patent/ES2223051T3/es
Priority to PCT/SE1995/000343 priority patent/WO1995027044A1/en
Priority to DE69533130T priority patent/DE69533130T2/de
Priority to JP7525612A priority patent/JPH09511143A/ja
Priority to AT95914666T priority patent/ATE268813T1/de
Priority to FI963860A priority patent/FI963860A0/fi
Priority to US09/061,912 priority patent/US6566093B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9401091A 1994-03-31 1994-03-31 Alphavirus cDNA vectors SE9401091D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors
AT95914666T ATE268813T1 (de) 1994-03-31 1995-03-30 Vektoren der alphavirus cdna
JP7525612A JPH09511143A (ja) 1994-03-31 1995-03-30 アルファーウイルスｃＤＮＡベクター
DK95914666T DK0753053T3 (da) 1994-03-31 1995-03-30 Alfavirus-cDNA-vektorer
EP95914666A EP0753053B1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS
AU21557/95A AU699384B2 (en) 1994-03-31 1995-03-30 Alphavirus cDNA vectors
CA002184261A CA2184261A1 (en) 1994-03-31 1995-03-30 Alphavirus cdna vectors
ES95914666T ES2223051T3 (es) 1994-03-31 1995-03-30 Vectores de adnc de alfavirus.
PCT/SE1995/000343 WO1995027044A1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS
DE69533130T DE69533130T2 (de) 1994-03-31 1995-03-30 VEKTOREN DER ALPHAVIRUS cDNA
FI963860A FI963860A0 (fi) 1994-03-31 1996-09-27 Alfavirus-cDNA-vektorit
US09/061,912 US6566093B1 (en) 1994-03-31 1998-04-17 Alphavirus cDNA vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors

Publications (1)

Publication Number Publication Date
SE9401091D0 true SE9401091D0 (sv) 1994-03-31

Family

ID=20393495

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors

Country Status (12)

Country Link
US (1) US6566093B1 (xx)
EP (1) EP0753053B1 (xx)
JP (1) JPH09511143A (xx)
AT (1) ATE268813T1 (xx)
AU (1) AU699384B2 (xx)
CA (1) CA2184261A1 (xx)
DE (1) DE69533130T2 (xx)
DK (1) DK0753053T3 (xx)
ES (1) ES2223051T3 (xx)
FI (1) FI963860A0 (xx)
SE (1) SE9401091D0 (xx)
WO (1) WO1995027044A1 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
ATE291632T1 (de) 1997-05-13 2005-04-15 Univ North Carolina Auf lentivirus basierende gentransfer-vektoren
FI110323B (fi) 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
EP1707633A1 (en) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
CA2309826A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
DK1029069T3 (da) * 1997-11-14 2006-12-18 Sanofi Pasteur Ltd Alphavirus-vektor
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2001275191A1 (en) 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
JP4790984B2 (ja) 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
MXPA04008890A (es) 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
PT1496939E (pt) 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
WO2004055167A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
ES2618309T3 (es) 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
ES2453344T3 (es) 2003-03-20 2014-04-07 Alphavax, Inc. Replicones de alfavirus mejorados y constructos cooperadores
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
CN1980955A (zh) * 2004-04-29 2007-06-13 北卡罗来纳-查佩尔山大学 增强细胞粘连特性的方法和组合物
US20050266550A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
CA2597921A1 (en) 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
KR20110044836A (ko) * 2008-05-23 2011-05-02 핏 바이오테크 오와이 알파바이러스 레플리카제를 코딩하는 발현 벡터 및 면역 보조제로서 이의 용도
CL2008002322A1 (es) * 2008-08-07 2009-06-05 Univ Concepcion Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
WO2011038063A1 (en) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
US20210040472A1 (en) 2019-08-09 2021-02-11 Nutcracker Therapeutics, Inc. Methods and apparatuses for manufacturing for removing material from a therapeutic composition
CN115197964A (zh) * 2021-04-12 2022-10-18 华南农业大学 一种改进型pSFV1载体及其制备方法与应用
CN113549652A (zh) * 2021-07-21 2021-10-26 华农（肇庆）生物产业技术研究院有限公司 SFV-helper质粒、pSFVCs-LacZ病毒样颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435224D1 (de) 1993-09-15 2009-09-10 Novartis Vaccines & Diagnostic Rekombinante Alphavirus-Vektoren

Also Published As

Publication number Publication date
DK0753053T3 (da) 2004-10-11
WO1995027044A1 (en) 1995-10-12
FI963860A (fi) 1996-09-27
JPH09511143A (ja) 1997-11-11
FI963860A0 (fi) 1996-09-27
EP0753053B1 (en) 2004-06-09
EP0753053A1 (en) 1997-01-15
DE69533130D1 (de) 2004-07-15
ATE268813T1 (de) 2004-06-15
AU699384B2 (en) 1998-12-03
ES2223051T3 (es) 2005-02-16
DE69533130T2 (de) 2005-07-07
CA2184261A1 (en) 1995-10-12
AU2155795A (en) 1995-10-23
US6566093B1 (en) 2003-05-20

Similar Documents

Publication Publication Date Title
DK0753053T3 (da) Alfavirus-cDNA-vektorer
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
DE69535376D1 (de) Expressionsvektor des alphavirus
IT7927940A0 (it) Estrattore chirurgico per asportare corpi estranei che si trovano nelle vie naturali del corpo umano, come calcoli e simili.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
EP0365598A4 (en) Therapeutic antimicrobial polypeptides, their use and methods for preparation
ES557100A0 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
FI844510L (fi) Ensym-resistenta immunsystemet modulerande peptider.
ATE95060T1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
ATE230985T1 (de) Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
TW200407425A (en) Human coagulation factor VII polypeptides
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
HUT40695A (en) Dna sequences, recombinant dna molecules and processes for preparing humane lipocortine like polypeptides
BR0213121A (pt) modelo in vitro para atividade priocidal
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
Wodzicka-Tomaszewska et al. Interactions between stress and boar stimulation in induction of puberty in gilts.
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
IT8220835A0 (it) Preparazione di soluzioni iniettabili di actinina impiegabili nella terapia umana come antalgico per il trattamento del dolore da neoplasie ed altre affezioni.